First Wave BioPharma Inc
FWBI
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.99M
Close$
$8.58
189.8% upside
Current Fair Value
189.8% upsideUndervalued by 189.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.99 Million |
|---|---|
| Enterprise Value | $8.10 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.16 |
| Beta | 1.28 |
| Outstanding Shares | 4,451,298 |
Return
| Return on Equity | -37.00% |
|---|---|
| Return on Assets | -18.21% |
| Return on Invested Capital | -31.12% |
Valuation & Multiples
| P/E Ratio | -2.86 |
|---|---|
| PEG | -1.65 |
| Price to Sales | - |
| Price to Book Ratio | 0.49 |
| Enterprise Value to Revenue | 108.79 |
| Enterprise Value to EBIT | -0.82 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.31 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About First Wave BioPharma Inc
12 employees
CEO: James Sapirstein AzurRx BioPharma, Inc. is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI assets. Th...